The Kenya Times on MSN
CS Ogamba releases 2025 KJSEA results
Education Cabinet Secretary Julius Ogamba has released the 2025 Kenya Junior School Education Assessment (KJSEA) results, ...
Education Cabinet Secretary Julius Migos Ogamba is set to release the first Kenya Junior School Education Assessment (KJSEA) results today, replacing the Kenya Certificate of Primary Education.
Newspoint on MSN
JKBOSE: Due to the cold weather, JKBOSE has decided that the 11th-grade practical exams will now be held at the schools; see the notice.
JKBOSE: The Jammu and Kashmir Board of School Education (JKBOSE) has issued an important notification regarding the external ...
BISC is an ultra-thin neural implant that creates a high-bandwidth wireless link between the brain and computers. Its tiny single-chip design packs tens of thousands of electrodes and supports ...
In the phase 3 COBRA trial, researchers sought to compare the efficacy of KRd to VRd in newly diagnosed multiple myeloma patients regardless of cytogenic risk or transplant eligibility.
We independently review everything we recommend. We may get paid to link out to retailer sites, and when you buy through our links, we may earn a commission. Learn more› By Mari Uyehara Mari Uyehara ...
Abstract: The practical consensus tracking problem is studied for a class of asynchronously switched multiagent systems (MASs). The asynchronous switchings are present in the followers, the leader, ...
Abbott made one of the biggest deals in recent medtech history last week when it announced its plan to acquire Exact Sciences — maker of colon cancer screening test Cologuard — for $23 billion.
Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...
MADISON, Wis. — Madison-based Exact Sciences, which leads the market with in-home cancer tests Cologuard and Oncotype DX, has been acquired by Abbott for around $21 billion. In the closing of the ...
Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results